---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031235"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:33:21.136075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anebulo Pharma Q1 FY2023 net loss $2.6M ($0.11/sh); positive ANEB-001 Phase 2 data

## Summary
- Net loss $2.6M vs $1.6M YoY; diluted EPS ($0.11) vs ($0.07).
- Cash $19.2M at Sept 30, 2022; cash burn $2.0M in quarter.
- Positive interim data for ANEB-001 from Phase 2 Part B announced.
- Closed $6.6M private placement financing in September 2022.
- Appointed Nat Calloway, Ph.D. to Board of Directors.

## SEC filing metadata
- accession: 0001493152-22-031235
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/0001493152-22-031235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031235
- JSON: https://secwatch.observer/filing/0001493152-22-031235.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031235.txt

## Key facts
- Earnings Releases
  Anebulo Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $(0.11) per share, EPS $(0.11) per share.
  - Period: the three months ended September 30, 2022
  - Net income: $(0.11) per share
  - EPS: $(0.11) per share
  - Result: reported results
  source text: Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/0001493152-22-031235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.